Neha Bhagwat

机构：Prelude Therapeutics Incorporated (United States) · ORCID：0009-0002-5766-0272

发表论文 169 篇 · 总被引 5796 次 · h-index 22

代表论文

• PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers (2025 · Cancer Research · 被引 20)
• Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies (2025 · Leukemia · 被引 14)
• Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma (2024 · Nature Communications · 被引 13)
• Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms (2023 · Cell Reports · 被引 9)
• PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer (2024 · Frontiers in Oncology · 被引 7)
• Discovery of first-in-class calr-targeted precision ADCs delivering a CDK9degrader payload for the treatment of calr-mutated MPNs (2025 · Blood · 被引 4)